Exelixis Reports Positive Results in Metastatic Castration-Resistant Prostate Cancer Study
Exelixis (NASDAQ: EXEL) already markets cabozantinib as a treatment for kidney cancer and liver cancer; its latest results suggest it may secure approval for its use in prostate cancer someday, too.
Interim results from a phase 1b trial showed that 32% of 44 metastatic castration-resistant prostate cancer (CRPC) patients responded to a combination of cabozantinib, which is marketed under the brand name Cabometyx, and Roche's (OTC: RHHBY) Tecentriq, a PD-1 inhibitor.
IMAGE SOURCE: GETTY IMAGES.
Source Fool.com
